Hormone therapy monitoring for young breast cancer patients
Part of Cancer, Skin clinical trials.
This study checks if a simple blood test can tell whether the monthly hormone injection is working well enough to keep estrogen levels low in young women with early breast cancer. It may help doctors adjust treatment to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 45
- You were diagnosed with early-stage breast cancer (stage I–III) that is hormone receptor-positive and HER2-negative
- You have completed surgery and any chemotherapy or radiation
- You are currently getting a 3-month injection (like Zoladex or Lupron) plus an aromatase inhibitor or tamoxifen
- Your blood test shows estradiol level of 30 pg/mL or higher within the last 28 days
- You are generally healthy (able to do daily activities, with normal organ function)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at young women with early-stage breast cancer who are premenopausal (still having periods) and have a low-to-intermediate Oncotype score, to see how well hormone therapy works. It aims to understand if current treatment decisions are appropriate.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
This Phase 2 study tests whether using hormone (endocrine) treatment alone can control breast cancer in people age 70 and older. It targets breast cancers that are estrogen-receptor positive and HER2 negative, aiming to avoid chemotherapy-like treatments in suitable patients.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This trial studies the safety of continuing endocrine therapy with ovarian suppression (for women) after you finish the earlier OVELIA study. It may help doctors confirm that the treatment remains safe for longer-term use.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.